Navigation Links
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
Date:5/20/2008

that utilizes MMX(R) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic components.

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the US, Canada, Pacific Rim, and Europe (excluding Italy). LIALDA is known as MEZAVANT XL(TM) in the UK and Ireland, and MEZAVANT(R) elsewhere outside of the US. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Media Sarah McGee (GolinHarris) +1 312 729 4125

Matthew Cabrey (Shire) +1 484 595 8248

About DDW

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscop
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... , CARTERSVILLE, Ga. ; June 2 ... Women (GASC) – Georgia ,s first fully ... minor gynecological surgeries in a true ... facility specializes in laparoscopic and other highly advanced, ...
... (Nasdaq: FHCO ) announced that it has fulfilled an order for 3.5 million ... World Cup. The 2010 World Cup will take place in The Republic of ... . , , , ... three million tickets to the games, is expected to flood the country with visitors. ...
Cached Medicine Technology:New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 3
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... and poor printing on prescription labels handed out ... to errors in taking medication, according to new ... (Canadian National Institute for the Blind)., The study, ... , found that labels on prescription medications dispensed ... guidelines for legibility. , By simply following recommended ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... Hologic, Inc.,(Nasdaq: HOLX ), a leading developer, ... and surgical products dedicated to,serving the healthcare needs ... quarter and fiscal 2008 operating results on Tuesday, ... the release, management will,host a conference call on ...
... Credentialing Center (ANCC) has designated Geisinger Medical Center (GMC) ... conference call to hospital administrators, nurses and staff who ... elite group of only 15 Pennsylvania hospitals and ... achieved Magnet status. More than 6,000 hospitals are eligible ...
... Delaying, avoiding radiation could lessen long-term side effects, study ... Using chemotherapy alone, and delaying or avoiding radiation altogether, ... progressive low-grade glioma brain tumors, according to a multi-institutional ... tumor in children. If surgery can be performed, the ...
... ANN ARBOR, Mich.---The University of Michigan received $5 million ... world,s leading resource of high-quality experimental data sets of ... to a new level. , The resource will ... can predict the effectiveness of potential new drugs, said ...
... CT adds metabolic information from PET to traditional CT ... maximized workflow ... quick return on investment, MUNICH, Germany, Oct. 10 ... new concept in,integrated imaging that provides a premium imaging ...
... ... Front Line, PHILADELPHIA, Oct. 9 ... more than,590 customer service representatives (CSRs), by rewarding them with fun,healthy activities ... 4 million inquiries a year, IBC,s CSRs are more than,just busy -- ...
Cached Medicine News:Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Chemo Alone Effective in Treating Kids' Brain Tumors 2Health News:U-M to house leading drug database 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4Health News:Independence Blue Cross Celebrates Customer Service Week 2
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
... High Throughput Screening (HTS), Analyst HT ... HTS by sharing all the detection ... AD, fluorescence intensity, fluorescence polarization, time-resolved ... seamless integration into robotic environments, including ...
... Designed for Ultra High Throughput ... multimode assay detection performance. Allows for ... from assay development by sharing all ... and HT, fluorescence intensity, fluorescence polarization, ...
Medicine Products: